Cargando…

Novel positive allosteric modulators of A(2B) adenosine receptor acting as bone mineralisation promoters

Small-molecules acting as positive allosteric modulators (PAMs) of the A(2B) adenosine receptor (A(2B) AR) could potentially represent a novel therapeutic strategy for pathological conditions characterised by altered bone homeostasis, including osteoporosis. We investigated a library of compounds (4...

Descripción completa

Detalles Bibliográficos
Autores principales: Barresi, Elisabetta, Giacomelli, Chiara, Marchetti, Laura, Baglini, Emma, Salerno, Silvia, Greco, Giovanni, Da Settimo, Federico, Martini, Claudia, Trincavelli, Maria Letizia, Taliani, Sabrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751416/
https://www.ncbi.nlm.nih.gov/pubmed/33334192
http://dx.doi.org/10.1080/14756366.2020.1862103
Descripción
Sumario:Small-molecules acting as positive allosteric modulators (PAMs) of the A(2B) adenosine receptor (A(2B) AR) could potentially represent a novel therapeutic strategy for pathological conditions characterised by altered bone homeostasis, including osteoporosis. We investigated a library of compounds (4-13) exhibiting different degrees of chemical similarity with three indole derivatives (1-3), which have been recently identified by us as PAMs of the A(2B) AR able to promote mesenchymal stem cell differentiation and bone formation. Evaluation of mineralisation activity of 4-13 in the presence and in the absence of the agonist BAY60-6583 allowed the identification of lead compounds with therapeutic potential as anti-osteoporosis agents. Further biological characterisation of one of the most performing compounds, the benzofurane derivative 9, confirmed that such a molecule behaves as PAM of the A(2B) AR.